The company is developing dedicated product lines for next-generation sequencing that incorporate a thermal cycler capable of 35-minute PCR.
The deal will focus on Biocartis' Idylla MSI test, which provides information on a tumor's microsatellite instability status of a tumor from a single FFPE slice.
In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
The trial will test two Bristol-Myers Squibb cancer drugs in patients with metastatic or unresectable tumors harboring mutations in the genes POLE and POLD1.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
The projects, organized by Friends of Cancer Research in the US and the Quality Assurance Initiative Pathology (QuIP) in Germany, are comparing different TMB assays.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.